Results 191 to 200 of about 3,635,661 (309)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

End Point Selection in ADPKD Clinical Trials. [PDF]

Kidney Int Rep
St Pierre K, El-Damanawi R, Jefferis J, Johnson DW, Hawley CM, Staatz CE, Viecelli AK, Mallett AJ.   +7 more
europepmc   +1 more source

Economics Notes: Economic modelling before clinical trials

, 2002
David Torgerson
openalex   +2 more sources

Tension-Free Vaginal Tape And Burch Colposuspension For Managing Stress Urinary Incontinence ( Types I And Ii ): A Comparative Clinical Trial [PDF]

, 2002
Mehwish Shazly, Nagwa A. Ghafar
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Safety reporting quality in multiple sclerosis clinical trials: A review of phase III clinical trials included in FDA approval of disease-modifying treatments. [PDF]

Mult Scler J Exp Transl Clin
Lin WZ, Lee JJ, Chertcoff A, Tremlett H, Kramer JLK.   +4 more
europepmc   +1 more source

Potential bias in ophthalmic pharmaceutical clinical trials

, 2008
Paul Varner
openalex   +2 more sources

A single-center, prospective, randomized clinical trial to study the effectiveness of exercise therapy in patients with CI-type Osteonecrosis of the femoral head: study protocol for a randomized controlled trial [PDF]

, 2019
Zhi Wu, Ming jia Zhang, Hai cheng Chen, Yang Zhao, Peng Wu, Zhi jun Yue, Duo rui Nie, Chi Zhou   +7 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Current Progress of Cell Therapy Clinical Trials in China in 2014-2024. [PDF]

Biomed Res Int
Shi W, Du C, Chen Z, Guo W, Li F, Zou Q, Feng S, Cai L, Yu Q.   +8 more
europepmc   +1 more source